Skip to main content

Home/ OARS funding Cancer/ Group items tagged biomed

Rss Feed Group items tagged

MiamiOH OARS

Fc-Dependent Mechanisms of Antibody-Mediated Killing (R21 Clinical Trial Not Allowed) - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites R21 applications for studies that address knowledge gaps in mechanisms of Fc-dependent, antibody-mediated killing of infected cells or aberrant cells, or antibody-mediated therapeutic ablation of cells implicated in immune pathologies, including autoimmune and allergic diseases. More specifically, the purpose of this FOA is to promote innovative and exploratory research to elucidate mechanisms of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP), and to promote development of tools, technologies, and animal models to facilitate identification and evaluation of cytotoxic killing mechanisms mediated by human antibodies in vivo.
MiamiOH OARS

Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinica... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies and blood biospecimens utilized as liquid biopsies. Extramural research funded under this FOA may include investigations of preanalytical variability relevant to diagnostic associated with the procurement and study of small biopsies (core biopsies, small excision samples), pleural aspirates, and blood utilized for liquid biopsies. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.
MiamiOH OARS

Children's Tumor Foundation Issues RFP for NF1 Gene Editing Research | RFPs | PND - 0 views

  •  
    The Children's Tumor Foundation has issued a Request for Proposals for research related to gene-based therapeutic approaches for the treatment of neurofibromatosis type 1 (NF1).

    The initiative will support proof of principle in vitro studies focused on the feasibility of genome editing techniques (including but not limited to those based on CRISPR-Cas9) to correct pathogenic mutations in NF1 gene. Funding for each study will be $240,000 total (inclusive of 10 percent indirect costs) over two years.
MiamiOH OARS

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) - 0 views

  •  
    The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.
MiamiOH OARS

Quantitative Imaging Tools and Methods for Cancer Response Assessment (R01 Clinical Tri... - 0 views

  •  
    This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging software tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative software tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those software tools in prospective multisite clinical trials to test software tool performance and to demonstrate that the software tool can be integrated into clinical workflow with a minimum of disruption.
MiamiOH OARS

Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not A... - 0 views

  •  
    The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins.
MiamiOH OARS

Prevention of HPV-related Cancers in HIV-infected individuals: United States-Latin Amer... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.
MiamiOH OARS

AACR Invites Applications for NextGen Cancer Research Grants | RFPs | PND - 0 views

  •  
    The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program.
    The annual program is designed to stimulate highly innovative research from young investigators. To that end, three-year grants of up to $450,000 will be awarded to promote and support creative, paradigm-shifting cancer research unlikely to be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants, research/laboratory supplies, equipment, travel applicable to the research project, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and indirect costs.

MiamiOH OARS

CCA Issues RFP for Young-Onset Colorectal Cancer Research | RFPs | PND - 0 views

  •  
    Founded in 1999, the Colorectal Cancer Alliance works to empower a nation of advocates to support patients, raise awareness of preventative measures, and inspire efforts to fund critical research. The alliance is committed to investing $10 million in critical research by 2021, including $3 million specifically to young-onset colorectal cancer research.

    To advance this goal, the alliance will award three Colorectal Cancer Alliance Chris4Life Research Grants in Young-Onset Colorectal Cancer Research in December 2018 (funding start date January 2019). Grant proposals will be considered in the categories of basic, translational, clinical, or epidemiological. Projects should focus on risk factors and causes associated with the rise in young-onset colorectal cancer, including but not limited to changes in the microbiome and its impact on young-onset colorectal cancer; prevention and early detection strategies for reducing the incidence and death rates associated with young-onset colorectal cancer; better mechanisms for increasing the long-term survival rates of those with young-onset colorectal cancer; and/or the psychosocial impacts of young-onset colorectal cancer and the overall social influence on daily survivorship.
MiamiOH OARS

RFA-CA-19-004: Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 -... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-19-012, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system.

MiamiOH OARS

RFA-CA-19-003: Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54 -... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.  

MiamiOH OARS

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Cl... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.
MiamiOH OARS

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Cl... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility.
MiamiOH OARS

LARGE-SCALE T CELL IMMUNE EPITOPE DISCOVERY - Federal Business Opportunities: Opportuni... - 0 views

  •  
    The primary purpose of this solicitation is to support highly interactive, multi-disciplinary teams, whose research efforts are focused on large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, and rejection of, or tolerance to, transplanted cells/organs/tissues. The discovery of epitopes associated with T cell responses to commensals and how they may be altered by the inflammatory state will also be supported by this solicitation. Validation of these epitopes and defining their role in immune protection or immune-mediated pathogenesis in humans is required. Investigators may include development/refinement of T cell epitope prediction tools as part of their research plan. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation, and either microbiologists and/or virologists with expertise in the target pathogen(s), clinicians with expertise in the target autoimmune diseases, or clinicians with expertise in transplantation, as appropriate. This program will not support studies related to HIV/AIDS, or allergen epitopes, including those which are infection-related.
MiamiOH OARS

PREVENT Cancer Preclinical Drug Development Program - Federal Business Opportunities: O... - 0 views

  •  
    The purpose of this solicitation is to procure Research & Development services to support the PREVENT Program in the areas of
    (1) in vivo development/animal efficacy/biomarker development,
    (2) preclinical product development and CGMP manufacturing of biopharmaceutical agents, and
    (3) toxicology/pharmacology testing.
MiamiOH OARS

Aniara Grant - 0 views

  •  
    Aniara Diagnostica's Coagulation Research Grant provides $20,000 for established investigators (eg - faculty at an academic institution) and for students/trainees to do innovative coagulation / hematology research. Deadline for receipt of application is November 1, 2018.
    The Aniara Research Panel awards one yearly $20,000 grant for specialized in hematology and coagulation research. All proposed projects must in the coagulation / hematology scientific field.
MiamiOH OARS

Bone Marrow Failure Idea Development Award - 0 views

  •  
    The BMFRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP vision of understanding and curing BMF diseases. This award mechanism is designed to support new ideas. Proposed research studies should have a high probability of revealing new avenues of investigation. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach. Personnel on the proposed team should have a strong background in BMF disease research.
MiamiOH OARS

DoD Ovarian Cancer Investigator-Initiated Research Award - 0 views

  •  
    The OCRP Investigator-Initiated Research Award is intended to support high-impact research that has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public. The anticipated direct costs budgeted for the entire period of performance for an FY18 OCRP Investigator-Initiated Research Award will not exceed $450,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of preclinical research. The standards are described in Landis, S.C., et al., A call for transparent reporting to optimize the predictive value of preclinical research, Nature 2012, 490:187-191.
MiamiOH OARS

Research Supplements to Promote Data Sharing in Cancer Epidemiology Studies (Admin Supp... - 0 views

  •  
    The purpose of the administrative supplement is to provide support for NIH-funded investigators to prepare and deposit individual-level data from cancer epidemiology studies into NIH/NCI-supported, controlled-access databases including the Cancer Epidemiology Data Repository (CEDR) and the database of Genotypes and Phenotypes (dbGaP). Sharing of research data will accelerate scientific discovery and increase opportunities for collaboration to provide new clues to cancer etiology, determine risk factors, and improve cancer survivorship.
MiamiOH OARS

DoD Breast Cancer, Breakthrough Fellowship Award - 0 views

  •  
    Breakthrough Fellowship Award supports recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research during their postdoctoral fellowship and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Those individuals should be exceptionally talented researchers who have demonstrated that they are the "best and brightest" of their peers. Applicants for this award must exhibit a strong desire to pursue a career in breast cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in breast cancer. Applicants must also demonstrate that the proposed research has high potential to lead to or make breakthroughs in breast cancer.
1 - 20 of 242 Next › Last »
Showing 20 items per page